On August 5, Novo-Nordisk A/S rose 3.14% overnight, trading at 46.38 USD/share, with turnover of $4.111 million.

On the news front, the company reported Q2 adjusted EPS of $0.96, beating the consensus estimate of $0.81 by 18.5%, while sales of $12.209 billion also exceeded the $11.35 billion estimate. The company simultaneously raised its full-year sales and operating profit guidance, primarily driven by elevated GLP-1 product sales expectations. Management reinforced positive signals during the earnings call, with the CEO highlighting that oral Wegovy has captured approximately 90% of the oral obesity drug market with 1.5 million users globally, and confirming plans for a near-term launch in Germany. The CFO stated the company has no plans for future cost-cutting and considers current pricing appropriately positioned.

The rebound follows a nearly 10% drop triggered by the failure of its heart drug ziltivekimab in a Phase 3 trial on July 31, suggesting markets are re-pricing the resilience of the core GLP-1 franchise despite mixed results in Wegovy oral and US injection sales that slightly missed segment-level expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)